Latest Prasugrel Stories
ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA(TM)/BRILIQUE(TM)) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.(1) These...
PARSIPPANY, N.J. and INDIANAPOLIS, March 15 /PRNewswire-FirstCall/ -- A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.
SAN DIEGO, March 15 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNowÂ® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced the presentation of a 2,000 patient meta-analysis examining patient response to antiplatelet therapy after percutaneous coronary intervention (PCI).
WALTHAM, Mass., Feb.
SAN DIEGO, Jan.
PARSIPPANY, N.J. and INDIANAPOLIS, Jan.
SAN DIEGO, Dec.
SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNowÂ® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents (e.g.
SAN DIEGO, Nov.
WILMINGTON, Del., Nov. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced it has submitted a New Drug Application (NDA) to the U.S.
- A gift; a largess; a gratuity; a present; a dole.